Phase 2 N=155 DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis
Plantar Fasciitis
Primary: Change From Baseline at Week 8 in the Numeric Pain Rating Scale (NPRS) Score — -3.29; -3.25; -2.75 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Daily Liraglutide for Nicotine Dependence
Smoking Cessation · Weight, Body
Primary: Number of Participants With 7-day Point Prevalence Smoking Abstinence at 12 Weeks Post-Target Quit Date — 2; 2 Participants
Phase 2 N=12 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer · KRAS Gene Mutation
Primary: Maximum Tolerated Dose of Ponatinib, Phase I — 30 mg of ponatinib
Phase 2 N=83 Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
Upper Limb Spasticity
Primary: Change From Baseline at Week 6 on the Modified Ashworth Scale (MAS) in the Suprahypertonic Muscle Group (SMG) Score — -0.9; -1.0; -1.5; -0.8 score on a scale — p=0.7645
Phase 2 N=114 Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation
Insomnia
Primary: Change From Baseline of Wakefulness After Sleep Onset (WASO) Measured by Polysomnography (PSG) — 100.88; 99.70; 103.51; 48.64 Minutes
Phase 2 N=108 Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis
HIV Infections · Tuberculosis
Primary: Virological Suppression at 24 Weeks — 43; 44 Participants
Phase 2 N=164 A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
Acute Myeloid Leukemia (AML)
Primary: Event-Free Survival (EFS) — 11.24; 7.72 months — p==0.477
Phase 2 N=164 Bonipar for Acute and Chronic Musculoskeletal Pain
Chronic Pain · Musculoskeletal Pain
Primary: Change in Pain as Measured by Subjective Pain Intensity Rating (SPIR) — -2.3; -2.6 score on a scale — p=0.46
Phase 2 N=60 A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
Choroideremia
Primary: Mean Best-Corrected Visual Acuity (BCVA) as Measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS) Chart in Letters at Month 12 — 68.0; 76.5; 82.3; 81.2…
Phase 2 N=16 StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis
Tuberculosis · Pulmonary Tuberculosis
Primary: Frequency of Grade 3 or Higher Adverse Events — 8; 4 AEs Grade 3 or Higher
Phase 2 N=21 Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy
Epilepsy
Primary: Dose Normalized Area Under the Concentration-Time Curve for Dosing Interval at Steady State (AUCtau,ss) of Perampanel During the Maintenance Period of the Core Phase for…
Phase 2 N=6 Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
Bone Marrow Failure Syndrome · Thalassemia · Sickle Cell Disease
Primary: Assessment of Minimum Effective Dose (MED) of Thiotepa — 5 mg/kg
Phase 2 N=41 A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)
Muscular Dystrophy, Duchenne
Primary: Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression as Measured by Western Blot Adjusted by Muscle Content — 4.23…
Phase 2 N=100 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
Phase 2 N=37 A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Mesothelioma · Uveal Melanoma · Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) — 5.6; 0 percentage of subjects